Recombinant Mouse VEGF 164 Protein

Formulations:
Catalog # Availability Size / Price Qty
493-MV-005
493-MV-025
Product Details
Citations (68)
FAQs
Reviews (6)

Recombinant Mouse VEGF 164 Protein Summary

Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED50 for this effect is 0.8-4 ng/mL.
Source
Spodoptera frugiperda, Sf 21 (baculovirus)-derived mouse VEGF protein
Ala27-Arg190
Accession #
N-terminal Sequence
Analysis
Ala27
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
19.4 kDa (monomer)
SDS-PAGE
42 kDa, non-reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

493-MV

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 50 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

493-MV/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 50 µg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: VEGF

Vascular endothelial growth factor (VEGF or VEGF‑A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1-3). It is a member of the PDGF family that is characterized by a cystine knot structure formed by eight conserved cysteine residues (4). Alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) have been identified in humans, with 120, 164 and 188 aa isoforms found in mouse (2, 4). Isoforms other than VEGF120 and VEGF121 contain basic heparin-binding regions and are not freely diffusible (4). Mouse VEGF164 shares 97% aa sequence identity with corresponding regions of rat, 89% with human and porcine, 88% with bovine, and 90% with feline, equine and canine VEGF, respectively. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). Human VEGF165 binds the semaphorin receptor, Neuropilin-1 and promotes complex formation with VEGF R2 (5). VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells (3, 4). In adults, VEGF functions mainly in wound healing and the female reproductive cycle (3). Pathologically, it is involved in tumor angiogenesis and vascular leakage (6, 7). Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (8). VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, oncostatin M and TNF-alpha (3, 4, 9).

References
  1. Breier, G. et al. (1992) Development 114:521.
  2. Shima, D.T. et al. (1996) J. Biol. Chem. 271:3877.
  3. Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777.
  4. Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. 114:853.
  5. Pan, Q. et al. (2007) J. Biol. Chem. 282:24049.
  6. Weis, S.M. and D.A. Cheresh (2005) Nature 437:497.
  7. Thurston, G. (2002) J. Anat. 200:575.
  8. Carvalho, J.F. et al. (2007) J. Clin. Immunol. 27:246.
  9. Angelo, L.S. and R. Kurzrock (2007) Clin. Cancer Res. 13:2825.
Long Name
Vascular Endothelial Growth Factor
Entrez Gene IDs
7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)
Alternate Names
MVCD1; VAS; vascular endothelial growth factor A; Vascular permeability factor; Vasculotropin; VEGF; VEGFA; VEGF-A; VEGFMGC70609; VPF; VPFvascular endothelial growth factor

Citations for Recombinant Mouse VEGF 164 Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

68 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. A histone deacetylase 7-derived peptide promotes vascular regeneration via facilitating 14-3-3gamma phosphorylation
    Authors: J Yang, A Moraga, J Xu, Y Zhao, P Luo, KH Lao, A Margariti, Q Zhao, W Ding, G Wang, M Zhang, L Zheng, Z Zhang, Y Hu, W Wang, L Shen, A Smith, AM Shah, Q Wang, L Zeng
    Stem Cells, 2019;0(0):.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Cell Culture
  2. Heterogeneity in old fibroblasts is linked to variability in reprogramming and wound healing
    Authors: S Mahmoudi, E Mancini, L Xu, A Moore, F Jahanbani, K Hebestreit, R Srinivasan, X Li, K Devarajan, L Prélot, CE Ang, Y Shibuya, BA Benayoun, ALS Chang, M Wernig, J Wysocka, MT Longaker, MP Snyder, A Brunet
    Nature, 2019;574(7779):553-558.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Cell Culture
  3. TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment
    Authors: P Zizza, R Dinami, M Porru, C Cingolani, E Salvati, A Rizzo, C D'Angelo, E Petti, CA Amoreo, M Mottolese, I Sperduti, A Chambery, R Russo, P Ostano, G Chiorino, G Blandino, A Sacconi, J Cherfils-V, C Leonetti, E Gilson, A Biroccio
    Nucleic Acids Res., 2019;0(0):.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  4. Age-related oxidative stress confines damage-responsive Bmi1+ cells to perivascular regions in the murine adult heart
    Authors: D Herrero, S Cañón, G Albericio, RM Carmona, S Aguilar, S Mañes, A Bernad
    Redox Biol, 2019;22(0):101156.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Dietary compound glycyrrhetinic acid suppresses tumor angiogenesis and growth by modulating antiangiogenic and proapoptotic pathways in vitro and in vivo
    Authors: J Li, F Tang, R Li, Z Chen, SM Lee, C Fu, J Zhang, GP Leung
    J. Nutr. Biochem., 2019;77(0):108268.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  6. EphrinB2 regulates VEGFR2 during dendritogenesis and hippocampal circuitry development
    Authors: E Harde, L Nicholson, B Furones Cu, D Bissen, S Wigge, S Urban, M Segarra, C Ruiz de Al, A Acker-Palm
    Elife, 2019;8(0):.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  7. ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models
    Authors: Y Li, JA Hickson, DJ Ambrosi, DL Haasch, KD Foster-Duk, LJ Eaton, EL Digiammari, SC Panchal, F Jiang, SR Mudd, C Zhang, SS Akella, W Gao, SL Ralston, L Naumovski, J Gu, SE Morgan-Lap
    Mol. Cancer Ther., 2018;0(0):.
    Applications: ELISA (Standard)
  8. Interleukin-18 Amplifies Macrophage Polarization and Morphological Alteration, Leading to Excessive Angiogenesis
    Authors: T Kobori, S Hamasaki, A Kitaura, Y Yamazaki, T Nishinaka, A Niwa, S Nakao, H Wake, S Mori, T Yoshino, M Nishibori, H Takahashi
    Front Immunol, 2018;9(0):334.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  9. Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease
    Authors: JM Gu, S Yuan, D Sim, K Abe, P Liu, M Rosenbruch, P Bringmann, K Kauser
    Exp. Hematol., 2018;0(0):.
    Species: Mouse
    Sample Types: Recombinant Protein
    Applications: ELISA (Capture)
  10. Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation
    Authors: G Del Monte-, M Ramialison, AAS Adam, B Wu, A Aharonov, G D'Uva, LM Bourke, ME Pitulescu, H Chen, JL de la Pomp, W Shou, RH Adams, SK Harten, E Tzahor, B Zhou, RP Harvey
    Nature, 2018;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Bioassay
  11. Extracellular Protein Fibulin-7 and Its C-Terminal Fragment Have In Vivo Antiangiogenic Activity
    Authors: T Ikeuchi, S de Vega, P Forcinito, AD Doyle, J Amaral, IR Rodriguez, E Arikawa-Hi, Y Yamada
    Sci Rep, 2018;8(1):17654.
  12. Muscle Satellite Cell Cross-Talk with a Vascular Niche Maintains Quiescence via VEGF and Notch Signaling
    Authors: M Verma, Y Asakura, BSR Murakonda, T Pengo, C Latroche, B Chazaud, LK McLoon, A Asakura
    Cell Stem Cell, 2018;23(4):530-543.e9.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  13. Intravital imaging-based analysis tools for vessel identification and assessment of concurrent dynamic vascular events
    Authors: N Honkura, M Richards, B Laviña, M Sáinz-Jasp, C Betsholtz, L Claesson-W
    Nat Commun, 2018;9(1):2746.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  14. Glycosylation controls cooperative PECAM-VEGFR2-?3 integrin functions at the endothelial surface for tumor angiogenesis
    Authors: R Imamaki, K Ogawa, Y Kizuka, Y Komi, S Kojima, N Kotani, K Honke, T Honda, N Taniguchi, S Kitazume
    Oncogene, 2018;0(0):.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  15. Novel combinatorial screening identifies neurotrophic factors for selective classes of motor neurons
    Authors: S Schaller, D Buttigieg, A Alory, A Jacquier, M Barad, M Merchant, D Gentien, P de la Gran, G Haase
    Proc. Natl. Acad. Sci. U.S.A, 2017;114(12):E2486-E2493.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  16. Intramyocardial Adipose-Derived Stem Cell Transplantation Increases Pericardial Fat with Recovery of Myocardial Function after Acute Myocardial Infarction
    Authors: Jong-Ho Kim
    PLoS ONE, 2016;11(6):e0158067.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  17. A 3D Poly(ethylene glycol)-based Tumor Angiogenesis Model to Study the Influence of Vascular Cells on Lung Tumor Cell Behavior
    Sci Rep, 2016;6(0):32726.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Osteoblasts secrete Cxcl9 to regulate angiogenesis in bone
    Nat Commun, 2016;7(0):13885.
    Species: Human
    Sample Types: Whole Cells
    Applications: Binding Assay
  19. Correction of MFG-E8 Resolves Inflammation and Promotes Cutaneous Wound Healing in Diabetes
    J Immunol, 2016;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Bioassay
  20. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways.
    Authors: Wang S, Amato K, Song W, Youngblood V, Lee K, Boothby M, Brantley-Sieders D, Chen J
    Mol Cell Biol, 2015;35(7):1299-313.
    Species: Mouse
    Sample Types: In Vivo
  21. Distinct functions of epidermal and myeloid-derived VEGF-A in skin tumorigenesis mediated by HPV8.
    Authors: Ding X, Lucas T, Marcuzzi G, Pfister H, Eming S
    Cancer Res, 2015;75(2):330-43.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  22. Factor VIIa binding to endothelial cell protein C receptor protects vascular barrier integrity in vivo.
    Authors: Sundaram, J, Keshava, S, Gopalakrishnan, R, Esmon, C T, Pendurthi, U R, Rao, L V M
    J Thromb Haemost, 2014;12(5):690-700.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  23. RAS interaction with PI3K p110alpha is required for tumor-induced angiogenesis.
    Authors: Murillo M, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, Downward J
    J Clin Invest, 2014;124(8):3601-11.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  24. Absence of CD9 reduces endometrial VEGF secretion and impairs uterine repair after parturition.
    Authors: Kawano, Natsuko, Miyado, Kenji, Yoshii, Noriko, Kanai, Seiya, Saito, Hidekazu, Miyado, Mami, Inagaki, Noboru, Odawara, Yasushi, Hamatani, Toshio, Umezawa, Akihiro
    Sci Rep, 2014;4(0):4701.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  25. Expression of podocalyxin separates the hematopoietic and vascular potentials of mouse embryonic stem cell-derived mesoderm.
    Authors: Zhang H, Nieves J, Fraser S, Isern J, Douvaras P, Papatsenko D, D'Souza S, Lemischka I, Dyer M, Baron M
    Stem Cells, 2014;32(1):191-203.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  26. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.
    Authors: Fleetwood F, Klint S, Hanze M, Gunneriusson E, Frejd F, Stahl S, Lofblom J
    Sci Rep, 2014;4(0):7518.
  27. A Snail1/Notch1 signalling axis controls embryonic vascular development.
    Authors: Wu Z, Rowe R, Lim K, Lin Y, Willis A, Tang Y, Li X, Nor J, Maillard I, Weiss S
    Nat Commun, 2014;5(0):3998.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  28. Circulating mouse Flk1+/c-Kit+/CD45- cells function as endothelial progenitors cells (EPCs) and stimulate the growth of human tumor xenografts.
    Authors: Russell J, Brown J
    Mol Cancer, 2014;13(0):177.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  29. Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors.
    Authors: Hunter, K E, Palermo, C, Kester, J C, Simpson, K, Li, J-P, Tang, L H, Klimstra, D S, Vlodavsky, I, Joyce, J A
    Oncogene, 2014;33(14):1799-808.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  30. The docking protein FRS2alpha is a critical regulator of VEGF receptors signaling.
    Authors: Chen P, Qin L, Zhuang Z, Tellides G, Lax I, Schlessinger J, Simons M
    Proc Natl Acad Sci U S A, 2014;111(15):5514-9.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  31. G protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression, and metastasis.
    Authors: Raghuwanshi S, Smith N, Rivers E, Thomas A, Sutton N, Hu Y, Mukhopadhyay S, Chen X, Leung T, Richardson R
    J Immunol, 2013;190(10):5329-36.
    Species: Mouse
    Sample Types: Tissue Homogenates
    Applications: ELISA (Control)
  32. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis.
    Authors: Zhang G, Panigrahy D, Mahakian L, Yang J, Liu J, Stephen Lee K, Wettersten H, Ulu A, Hu X, Tam S, Hwang S, Ingham E, Kieran M, Weiss R, Ferrara K, Hammock B
    Proc Natl Acad Sci U S A, 2013;110(16):6530-5.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  33. Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitro.
    Authors: Iwasaki T, Takeda Y, Maruyama K, Yokosaki Y, Tsujino K, Tetsumoto S, Kuhara H, Nakanishi K, Otani Y, Jin Y, Kohmo S, Hirata H, Takahashi R, Suzuki M, Inoue K, Nagatomo I, Goya S, Kijima T, Kumagai T, Tachibana I, Kawase I, Kumanogoh A
    J Biol Chem, 2013;288(4):2118-31.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Bioassay
  34. Regulation of innate CD8+ T-cell activation mediated by cytokines.
    Proc Natl Acad Sci U S A, 2012;109(25):9971-6.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  35. VEGFA family isoforms regulate spermatogonial stem cell homeostasis in vivo.
    Authors: Caires KC, de Avila JM, Cupp AS
    Endocrinology, 2012;153(2):887-900.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  36. Flt-1 regulates vascular endothelial cell migration via a protein tyrosine kinase-7-dependent pathway.
    Authors: Lee HK, Chauhan SK, Kay E
    Blood, 2011;117(21):5762-71.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  37. Smad1 signaling restricts hematopoietic potential after promoting hemangioblast commitment.
    Authors: Cook BD, Liu S, Evans T
    Blood, 2011;117(24):6489-97.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  38. Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1.
    Authors: Ruiz de Almodovar C, Coulon C, Salin PA, Knevels E, Chounlamountri N, Poesen K, Hermans K, Lambrechts D, Van Geyte K, Dhondt J, Dresselaers T, Renaud J, Aragones J, Zacchigna S, Geudens I, Gall D, Stroobants S, Mutin M, Dassonville K, Storkebaum E, Jordan BF, Eriksson U, Moons L, D'Hooge R, Haigh JJ, Belin MF, Schiffmann S, Van Hecke P, Gallez B, Vinckier S, Chedotal A, Honnorat J, Thomasset N, Carmeliet P, Meissirel C
    J. Neurosci., 2010;30(45):15052-66.
    Species: Mouse
    Sample Types: Cell Culture Supernates
    Applications: Bioassay
  39. Inhibition of endothelial progenitor cell differentiation by VEGI.
    Authors: Tian F, Liang PH, Li LY
    Blood, 2009;113(21):5352-60.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  40. Dysfunctional microvasculature as a consequence of shb gene inactivation causes impaired tumor growth.
    Authors: Funa NS, Kriz V, Zang G, Calounova G, Akerblom B, Mares J, Larsson E, Sun Y, Betsholtz C, Welsh M
    Cancer Res., 2009;69(5):2141-8.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  41. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment.
    Authors: Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N
    Cancer Cell, 2009;15(1):21-34.
    Species: N/A
    Sample Types: N/A
    Applications: Western Blot
  42. Production of scFv antibody fragments from a hybridoma with functional activity against human vascular endothelial growth factor.
    Authors: Irani Y, Brereton HM, Tilton RG
    Hybridoma (Larchmt), 2009;28(3):205-9.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Binding Assay
  43. The Down syndrome critical region gene 1 short variant promoters direct vascular bed-specific gene expression during inflammation in mice.
    Authors: Minami T, Yano K, Miura M, Kobayashi M, Suehiro J, Reid PC, Hamakubo T, Ryeom S, Aird WC, Kodama T
    J. Clin. Invest., 2009;119(8):2257-70.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  44. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1.
    Authors: Ponticelli S, Marasco D, Tarallo V, Albuquerque RJ, Mitola S, Takeda A, Stassen JM, Presta M, Ambati J, Ruvo M, De Falco S
    J. Biol. Chem., 2008;283(49):34250-9.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  45. Interaction between bevacizumab and murine VEGF-A: a reassessment.
    Authors: Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N
    Invest. Ophthalmol. Vis. Sci., 2008;49(2):522-7.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  46. Regulation of scar formation by vascular endothelial growth factor.
    Authors: Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, DiPietro LA
    Lab. Invest., 2008;88(6):579-90.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  47. Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor.
    Authors: Nyberg P, Xie L, Sugimoto H, Colorado P, Sund M, Holthaus K, Sudhakar A, Salo T, Kalluri R
    Exp. Cell Res., 2008;314(18):3292-305.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  48. Adenoviral expression of vascular endothelial growth factor splice variants differentially regulate bone marrow-derived mesenchymal stem cells.
    Authors: Lin H, Shabbir A, Molnar M, Yang J, Marion S, Canty JM, Lee T
    J. Cell. Physiol., 2008;216(2):458-68.
    Species: Porcine
    Sample Types: Whole Cells
    Applications: Bioassay
  49. Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation.
    Authors: Noman AS, Koide N, Khuda II, Dagvadorj J, Tumurkhuu G, Naiki Y, Komatsu T, Yoshida T, Yokochi T
    Biochem. Biophys. Res. Commun., 2008;374(4):683-7.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  50. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice.
    Authors: Zheng C, Skold MK, Li J, Nennesmo I, Fadeel B, Henter JI
    Biochem. Biophys. Res. Commun., 2007;363(4):989-93.
  51. alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner.
    Authors: Zhang Z, Ramirez NE, Yankeelov TE, Li Z, Ford LE, Qi Y, Pozzi A, Zutter MM
    Blood, 2007;111(4):1980-8.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  52. Inactivation of VEGF in mammary gland epithelium severely compromises mammary gland development and function.
    Authors: Rossiter H, Barresi C, Ghannadan M, Gruber F, Mildner M, Fodinger D, Tschachler E
    FASEB J., 2007;21(14):3994-4004.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  53. Bv8 regulates myeloid-cell-dependent tumour angiogenesis.
    Authors: Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, Ho C, Ross J, Tan M, Carano RA, Meng YG, Ferrara N
    Nature, 2007;450(7171):825-31.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  54. Corneal avascularity is due to soluble VEGF receptor-1.
    Authors: Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM, Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP, De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J
    Nature, 2006;443(7114):993-7.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  55. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta.
    Authors: Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L, Evan GI
    Genes Dev., 2006;20(18):2527-38.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  56. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro.
    Authors: Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, Wang J, Ling V, Sun L
    Chem. Biol., 2006;13(5):549-56.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  57. Cardiac arterial pole alignment is sensitive to FGF8 signaling in the pharynx.
    Authors: Hutson MR, Zhang P, Stadt HA, Sato AK, Li YX, Burch J, Creazzo TL, Kirby ML
    Dev. Biol., 2006;295(2):486-97.
    Species: Chicken
    Sample Types: Whole Cells
    Applications: Bioassay
  58. VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain.
    Authors: Le Bras B, Barallobre MJ, Homman-Ludiye J, Ny A, Wyns S, Tammela T, Haiko P, Karkkainen MJ, Yuan L, Muriel MP, Chatzopoulou E, Breant C, Zalc B, Carmeliet P, Alitalo K, Eichmann A, Thomas JL
    Nat. Neurosci., 2006;9(3):340-8.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  59. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action.
    Authors: Cao R, Bjorndahl MA, Gallego MI, Chen S, Religa P, Hansen AJ, Cao Y
    Blood, 2006;107(9):3531-6.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  60. Cytokine-containing gelfoam implants at a postsurgical tumor excision site to stimulate local immune reactivity.
    Authors: Young MR
    Int. J. Cancer, 2006;119(1):133-8.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  61. VEGF-A signaling through Flk-1 is a critical facilitator of early embryonic lung epithelial to endothelial crosstalk and branching morphogenesis.
    Authors: Del Moral PM, Sala FG, Tefft D, Shi W, Keshet E, Bellusci S, Warburton D
    Dev. Biol., 2005;290(1):177-88.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  62. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.
    Authors: Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP
    Invest. Ophthalmol. Vis. Sci., 2004;45(2):368-74.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  63. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.
    Authors: Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C
    J. Cell Biol., 2003;161(6):1163-77.
    Species: Rat
    Sample Types: In Vivo
    Applications: In Vivo
  64. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay.
    Authors: Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, Stetler-Stevenson WG
    Am. J. Pathol., 2003;162(5):1431-9.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  65. Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.
    Authors: Yi M, Sakai T, Fassler R, Ruoslahti E
    Proc. Natl. Acad. Sci. U.S.A., 2003;100(20):11435-8.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  66. Inhibition of programmed cell death impairs in vitro vascular-like structure formation and reduces in vivo angiogenesis.
    Authors: Segura I, 2019, Serrano A, De Buitrago GG, Gonzalez MA, Abad JL, Claveria C, Gomez L, Bernad A, Martinez-A C, Riese HH
    7096, 2002;16(8):833-41.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  67. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients.
    Authors: Young PP, Hofling AA, Sands MS
    Proc. Natl. Acad. Sci. U.S.A., 2002;99(18):11951-6.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  68. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins.
    Authors: Halin C, Niesner U, Villani ME, Zardi L, Neri D
    Int. J. Cancer, 2002;102(2):109-16.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo

FAQs

  1. The vial is supposed to contain lyophilized protein but it appears to be empty. Is there anything in it?

    • Pellets can be dislodged during shipping and become disbursed on the vial wall and in the cap. Centrifuge or tap the vial on the benchtop to return this material to the vial bottom. If this does not reveal a pellet, closely inspect the cone of the vial. Some pellets appear as only a tiny amount of material or as a transparent film due to the original buffer formulation. This is a normal appearance for many proteins. For example, if the product is originally lyophilized from a solvent such as acetonitrile or ethanol, and supplied carrier-free, you may not be able to detect the pellet with the naked eye. This does not mean the vial is empty. Reconstitute the vial as directed. After reconstitution, protein concentration can be tested with a spectrophotometer.

  2. What is the recommended method for reconstitution of a lyophilized protein or antibody?

    • Unless more specific directions are on the Certificate of Analysis provided with the product, we suggest the following procedure to ensure optimal recovery: 1. Allow the vial and reconstitution buffer to equilibrate to room temperature. 2. Briefly centrifuge the vial to ensure that all lyophiliate is collected at the bottom of the vial. 3. Add the amount of buffer required to achieve the concentration recommended on the product insert. 4. Allow the vial to reconstitute for 15-30 minutes at room temperature with gentle agitation, like on a rocker platform or rotating by hand.  Avoid vigorous shaking that can cause foaming and protein denaturation. 5. Aliquot into volumes greater than 20 μL and store as indicated on the product insert. If the vial exhibits flakes or particulates, mix the product for a couple of hours at room temperature and then at 4oC overnight. Contact Technical Service if product does not go into solution.  

       

  3. Are R&D Systems recombinant proteins and antibodies sterile?

    • Although the vials are bottled using aseptic techniques, heat-treated vials, and sterile stock solutions, they are not considered or guaranteed to be sterile. If sterile material is needed for an experiment, the material can be filtered through a 0.2 micron filter designed for use with biological fluids.

View all Proteins and Enzyme FAQs

Reviews for Recombinant Mouse VEGF 164 Protein

Average Rating: 4.8 (Based on 6 Reviews)

5 Star
83.33%
4 Star
16.67%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Mouse VEGF 164 Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Mouse VEGF 164 Protein
By Anonymous on 10/17/2019
Application: Cell Adhesion

Recombinant Mouse VEGF 164 Protein
By Anonymous on 05/03/2018
Application: CellProlif

Recombinant Mouse VEGF 164 Protein
By Anonymous on 04/26/2018
Application: SDS-PAGE Control

Recombinant Mouse VEGF 164 Protein
By Anonymous on 04/22/2018
Application: CellProlif

Recombinant Mouse VEGF 164 Protein
By Anonymous on 04/17/2018
Application: Other

Recombinant Mouse VEGF 164 Protein
By Anonymous on 06/13/2017
Application: VEGFA effect on p38MAPK activation in mouse retinal epithelial cells